Budai Barna, Hitre Erika, Adleff Vilmos, Czeglédi Ferenc, Gyergyay Fruzsina, Láng István, Kralovánszky Judit
Országos Onkológiai Intézet, Budapest 1122, Hungary.
Magy Onkol. 2004;48(3):253-7. Epub 2004 Nov 1.
The authors investigated the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in 101 metastatic colorectal cancer patients treated with 5-fluoropyrimidine-based therapy and in 196 healthy individuals by PCR-RFLP method. There was no significant difference in genotype distribution of patients and healthy controls, and between subgroups investigated according to clinical parameters (age, gender, tumor location, grade and treatment type). However, after a 3-30 (median 18.5) months follow-up the survival of patients with T allele proved to be better than that of patients with wild type (CC) genotype (p=0.036). In case of CT and TT genotypes the survival of patients receiving only first line therapy was significantly shorter than that of patients receiving more lines of treatment (p=0.015). Determination of MTHFR C677T polymorphism has prognostic value in case of patients with metastatic colorectal cancer receiving 5-fluoropyrimidine-based therapy, and may help in designing the individual (group) tailored therapy.
作者采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法，对101例接受基于5-氟嘧啶治疗的转移性结直肠癌患者及196名健康个体的亚甲基四氢叶酸还原酶（MTHFR）C677T基因多态性进行了研究。患者与健康对照的基因型分布，以及根据临床参数（年龄、性别、肿瘤位置、分级和治疗类型）划分的亚组之间，均无显著差异。然而，经过3至30个月（中位时间18.5个月）的随访，携带T等位基因的患者生存率优于野生型（CC）基因型患者（p = 0.036）。在CT和TT基因型患者中，仅接受一线治疗的患者生存率显著低于接受多线治疗的患者（p = 0.015）。对于接受基于5-氟嘧啶治疗的转移性结直肠癌患者，MTHFR C677T基因多态性检测具有预后价值，可能有助于设计个体化（分组）的定制治疗方案。
